NK 314

Drug Profile

NK 314

Alternative Names: NK314

Latest Information Update: 05 May 2008

Price : $50

At a glance

  • Originator Nippon Kayaku
  • Class Antineoplastics; Phenanthrenes
  • Mechanism of Action DNA activated protein kinase inhibitors; DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical T cell lymphoma

Most Recent Events

  • 16 Apr 2008 Preclinical trials in T-cell lymphoma in Japan (unspecified route)
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 20 Jan 2004 Preclinical trials in Solid tumours in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top